Heart failure & cardiomyopathiesGuideline or statement
Workup and management of rhythm disorders in myocarditis and inflammatory cardiomyopathy: a clinical consensus statement of the European Heart Rhythm Association and the Heart Failure Association of the European Society of Cardiology (ESC), the ESC Working Group on Myocardial & Pericardial Diseases, the European Association of Preventive Cardiology of the ESC, the Heart Rhythm Society, the Asian Pacific Heart Rhythm Society, and the Latin American Heart Rhythm Society
- Clinical consensus statement
Recommendations
As issued by the authors
Arrhythmia management is stratified by disease phase.
During active inflammation, antiarrhythmic therapy is combined with aetiology-targeted treatment or immunosuppression when indicated.
In later stages, substrate-based strategies include pharmacological therapy, device implantation, or ablation.
Emphasis on hot-to-cold transition as an arrhythmogenic window and on risk stratification.
Original publication
Workup and management of rhythm disorders in myocarditis and inflammatory cardiomyopathy: a clinical consensus statement of the European Heart Rhythm Association and the Heart Failure Association of the ESC, the ESC Working Group on Myocardial & Pericardial Diseases, the European Association of Preventive Cardiology of the ESC, the Heart Rhythm Society, the Asian Pacific Heart Rhythm Society, and the Latin American Heart Rhythm Society. Europace. Published 28 August 2026. doi:10.1093/europace/euag153
Summarised from the published abstract; every number is checked against it